What do Pope Francis, Edward Snowden and Stelara have in common?
They all share mention in the top newsmakers of 2013.
Of course, we at the National Psoriasis Foundation are most interested in psoriatic disease research news. So we polled several experts in our community for their psoriatic disease research highlights in 2013.
- Food and Drug Administration (FDA) approvals for two new psoriatic arthritis treatments – Stelara (ustekinumab) and Cimzia (certolizumab.)
- Several drugs are performing well in clinical trials, including:
- Celgene, which produces the oral drug apremilast, has asked the FDA to approve the drug as a treatment for psoriatic arthritis. At week 52, 63 percent of patients in the study on a 20-milligram dose saw a reduction in pain and stiffness. Learn more about apremilast »
- Brodalumab, ixekizumab and secukinumab, three biologic drugs that target a protein in the immune system called interleukin 17 or its receptor that is linked to psoriasis and psoriatic arthritis inflammation, are performing well in trials.
- A study in the United Kingdom showed treating psoriatic arthritis more aggressively yielded better results.
- A large study of 34 dermatology clinics in Europe and North America showed that 10 percent of psoriasis patients had undiagnosed psoriatic arthritis. This is perhaps not a highlight, in the strictest sense of the word, but it is important.
- Again, the success of IL-17 inhibitors (ixekizumab and secukinumab) and the IL-17 receptor inhibitor (brodalumab) was noted as a significant. All drugs are performing as well as, or better than, existing biologics in the market, at least in clinical trials.
- Tofacitinib, an oral drug that targets janus kinase, an enzyme linked to psoriasis inflammation, also is performing well in Phase II clinical trials.
- Several studies further examine the link between psoriasis and other related medical conditions. One study published in the Journal of the American Medical Association showed that children with psoriasis are more likely to be obese and to carry excess weight around the midsection. As a result, they are more likely to be at risk for metabolic syndrome. Another paper adds further proof to the link between psoriasis and cardiovascular disease. The paper, published in the Journal of the American Heart Association, showed that people with psoriasis are not only more likely to develop cardiovascular disease, but that the risk of developing cardiovascular disease increases with the severity of psoriasis.
The following researchers and medical doctors were consulted for this list:
Arthur Kavanaugh, M.D.
University of California, San Diego
Elaine Husni, M.D.
Cleveland Clinic, Ohio
Christopher Ritchlin, M.D.
University of Rochester Medical Center
Andy Robertson, Ph.D
National Psoriasis Foundation
Chief Medical and Scientific Officer
Alice Gottlieb, M.D., Ph.D
Tufts Medical Center
Paul Yamauchi, M.D., Ph.D.
University of California, Los Angeles
Mark Lebwohl, M.D.
Icahn School of Medicine at Mount Sinai
Alan Menter, M.D.
Texas Dermatology Associates
April Armstrong, M.D., M.P.H.
University of Colorado
Sarah Kurts, P.A.-C
Dermatology and Laser Institute of Colorado
Ron Prussick, M.D., F.R. C.P.
George Washington University
Joel Gelfand, M.D., M.S.C.E.
University of Pennsylvania
Jerry Krueger, M.D.
University of Utah Medical School